最後更新：2026年10月1日
骨關節炎（OA）疼痛是犬最常見的慢性疼痛來源，影響約 20% 的成年犬。疼痛涉及發炎性與神經性成分。長期多模式管理（藥物、體重、運動、物理治療）為最佳策略。
貓的疾病表現常較犬隱匿，需注意細微行為變化
可點的項目會開啟該疾病頁。要依症狀與檢驗排出完整清單，請用鑑別診斷工具。
丁基原啡因。Analgesic
納布啡。Opioid analgesic (Agonist-antagonist)
加巴噴丁。Gabapentinoid (Anticonvulsant / Analgesic)
建議：依臨床狀況調整
| 藥物 | 劑量 | 頻率 | 路徑 | 優先級 |
|---|---|---|---|---|
| Buprenorphine Hydrochloride 丁基原啡因。Analgesic | 犬 0.01-0.02 mg/kg q6-12h IV/IM；貓 0.01-0.03 mg/kg q6-12h IV/IM | Q6-12H | IV | 首選 |
| Nalbuphine 納布啡。Opioid analgesic (Agonist-antagonist) | 犬 0.1-0.5 mg/kg q4-6h IV/IM/SC；貓 0.05-0.2 mg/kg q4-6h IV/IM/SC | Q4-6H | IV | 首選 |
| 藥物 | 劑量 | 頻率 | 優先級 |
|---|---|---|---|
| Co-danthramer, Co-danthrusate 丹蒽醌複方。Antibacterial | 犬 10-20 mg/kg q12h PO；貓 10-15 mg/kg q12h PO | Q12H | 首選 |
| Gabapentin 加巴噴丁。Gabapentinoid (Anticonvulsant / Analgesic) | 犬 5-10 mg/kg q8-12h PO；貓 5-10 mg/kg q8-12h PO | Q8-12H | 首選 |
監測頻率：依病因
[1]Physical Activity Monitors in Companion Animal Chronic Pain Research-A Review Focused on Osteoarthritis Pain.
[2]Beyond Osteoarthritis: Emerging Applications of Anti-NGF Monoclonal Antibodies in Pain Management in Dogs and Cats.
[3]Pain Treatment in the Companion Canine Model to Validate Rodent Results and Incentivize the Transition to Human Clinical Trials.
[4]Osteoarthritis pain: What are we learning from animal models?
[5]Multiple session mesotherapy for management of coxofemoral osteoarthritis pain in 10 working dogs: A case series.
需系統性診斷與治療計畫，延遲可能影響預後 (systematic workup needed, delay may affect prognosis)
OA 為進行性疾病，疼痛管理為終生需求。多模式管理可有效控制疼痛。Librela（抗NGF抗體）為新型長效止痛選項。體重管理是最重要的可修改因素。
Diagnostic Approach for Osteoarthritis Pain
Thorough history collection; complete physical examination with attention to presenting complaint
CBC, serum chemistry panel, urinalysis; additional tests based on clinical findings
Advanced imaging, specialized testing, or referral based on minimum database findings